Canntab Therapeutics Limited
Canntab Therapeutics Limited, a phytopharmaceutical company, engages in the research and development of advanced pharmaceutical grade formulations of cannabinoids in Canada. It offers oral dosage formulations of pharmaceutical cannabis, including sustained release cannabinoid formulations and pellets, immediate release cannabidiol formulations, modified-release multi-layer cannabinoid formulation… Read more
Canntab Therapeutics Limited (CTABF) - Net Assets
Latest net assets as of February 2023: $-2.16 Million USD
Based on the latest financial reports, Canntab Therapeutics Limited (CTABF) has net assets worth $-2.16 Million USD as of February 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($953.54K) and total liabilities ($3.11 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-2.16 Million |
| % of Total Assets | -226.49% |
| Annual Growth Rate | N/A |
| 5-Year Change | -107.23% |
| 10-Year Change | -894.32% |
| Growth Volatility | 677.31 |
Canntab Therapeutics Limited - Net Assets Trend (2011–2022)
This chart illustrates how Canntab Therapeutics Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Canntab Therapeutics Limited (2011–2022)
The table below shows the annual net assets of Canntab Therapeutics Limited from 2011 to 2022.
| Year | Net Assets | Change |
|---|---|---|
| 2022-05-31 | $-311.22K | -113.72% |
| 2021-05-31 | $2.27 Million | -35.71% |
| 2020-05-31 | $3.53 Million | +55.60% |
| 2019-05-31 | $2.27 Million | -47.29% |
| 2018-05-31 | $4.30 Million | +3014.65% |
| 2017-12-31 | $-147.60K | -114.21% |
| 2017-05-31 | $1.04 Million | +1693.90% |
| 2016-12-31 | $-65.16K | -106.93% |
| 2016-05-31 | $940.23K | +2299.70% |
| 2015-05-31 | $39.18K | -81.78% |
| 2014-05-31 | $215.05K | +78.42% |
| 2013-05-31 | $120.53K | -79.27% |
| 2012-05-31 | $581.44K | -20.20% |
| 2011-05-31 | $728.59K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Canntab Therapeutics Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1659904900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (May 2022)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $13.44 Million | % |
| Other Components | $2.94 Million | % |
| Total Equity | $-311.22K | 100.00% |
Canntab Therapeutics Limited Competitors by Market Cap
The table below lists competitors of Canntab Therapeutics Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hansol Homedeco Co. Ltd.
KQ:025750
|
$3.87K |
|
Fable Media Group AB
ST:FABLE
|
$3.88K |
|
Detalion Games S.A.
WAR:DEG
|
$3.88K |
|
North PetroVietnam Fertilizer & Chemicals JSC
VN:PMB
|
$3.88K |
|
CWWGF
PINK:CWWGF
|
$3.87K |
|
COMPAGNIE IMMOBILI
SEM:CIMO
|
$3.86K |
|
CAP LEASE AVIATION
LSE:CLA
|
$3.85K |
|
TOTALENERGIES MARKETING NIGERIA PLC
XNSA:TOTAL
|
$3.85K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Canntab Therapeutics Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from 2,268,758 to -311,223, a change of -2,579,981 (-113.7%).
- Net loss of 3,689,186 reduced equity.
- Other comprehensive income decreased equity by 813,750.
- Other factors increased equity by 1,922,955.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-3.69 Million | -1185.38% |
| Other Comprehensive Income | $-813.75K | -261.47% |
| Other Changes | $1.92 Million | +617.87% |
| Total Change | $- | -113.72% |
Book Value vs Market Value Analysis
This analysis compares Canntab Therapeutics Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-05-31 | $12.00 | $0.00 | x |
| 2012-05-31 | $3.76 | $0.00 | x |
| 2013-05-31 | $0.64 | $0.00 | x |
| 2014-05-31 | $1.09 | $0.00 | x |
| 2015-05-31 | $0.26 | $0.00 | x |
| 2016-05-31 | $4.08 | $0.00 | x |
| 2016-12-31 | $0.00 | $0.00 | x |
| 2017-05-31 | $0.07 | $0.00 | x |
| 2017-12-31 | $0.00 | $0.00 | x |
| 2018-05-31 | $0.20 | $0.00 | x |
| 2019-05-31 | $0.09 | $0.00 | x |
| 2020-05-31 | $0.13 | $0.00 | x |
| 2021-05-31 | $0.07 | $0.00 | x |
| 2022-05-31 | $-0.01 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Canntab Therapeutics Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1257.55%
- • Asset Turnover: 0.10x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-193.59%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | -13.78% | 0.00% | 0.00x | 1.17x | $-173.27K |
| 2012 | -249.69% | -14293.36% | 0.01x | 1.17x | $-1.51 Million |
| 2013 | -1292.05% | 0.00% | 0.00x | 1.66x | $-1.57 Million |
| 2014 | -140.08% | 0.00% | 0.00x | 1.59x | $-322.75K |
| 2015 | -455.66% | 0.00% | 0.00x | 7.20x | $-182.45K |
| 2016 | -18.49% | 0.00% | 0.00x | 1.43x | $-267.86K |
| 2016 | 0.00% | 55.16% | 55.23x | 0.00x | $526.29K |
| 2017 | -107.48% | -118.45% | 0.83x | 1.10x | $-1.22 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-167.69K |
| 2018 | -55.98% | -9031.44% | 0.01x | 1.10x | $-2.84 Million |
| 2019 | -108.41% | -1024.41% | 0.09x | 1.14x | $-2.69 Million |
| 2020 | -73.89% | -1955.42% | 0.02x | 1.56x | $-2.96 Million |
| 2021 | -194.81% | 0.00% | 0.00x | 2.80x | $-4.65 Million |
| 2022 | 0.00% | -1257.55% | 0.10x | 0.00x | $-3.66 Million |
Industry Comparison
This section compares Canntab Therapeutics Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Canntab Therapeutics Limited (CTABF) | $-2.16 Million | -13.78% | N/A | $3.87K |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |